$WVE
Wave Life Sciences Ltd.

2024 Q1 Form 10-K Financial Statement

#000095017024026876 Filed on March 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $12.54M $29.06M $113.3M
YoY Change -3.02% 2245.12% 3005.1%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.55M $13.66M $51.29M
YoY Change 10.74% -0.44% 1.54%
% of Gross Profit
Research & Development $33.45M $34.07M $130.0M
YoY Change 7.97% 9.64% 12.22%
% of Gross Profit
Depreciation & Amortization $1.042M $1.081M $5.000M
YoY Change -27.29% -28.51% -24.24%
% of Gross Profit
Operating Expenses $47.00M $47.74M $181.3M
YoY Change 8.75% 6.55% 8.98%
Operating Profit -$34.46M -$68.00M
YoY Change 13.78% -58.21%
Interest Expense $2.535M $1.844M $7.928M
YoY Change 35.34% 123.52% 404.65%
% of Operating Profit
Other Income/Expense, Net $2.900M $582.0K $9.806M
YoY Change 0.69% -300.69% 521.42%
Pretax Income -$31.56M -$16.26M -$58.19M
YoY Change 15.15% -62.22% -63.89%
Income Tax $0.00 $0.00 -$677.0K
% Of Pretax Income
Net Earnings -$31.56M -$16.26M -$57.51M
YoY Change 15.15% -62.81% -64.46%
Net Earnings / Revenue -251.7% -55.95% -50.76%
Basic Earnings Per Share -$0.24 -$0.54
Diluted Earnings Per Share -$0.24 -$0.15 -$0.54
COMMON SHARES
Basic Shares Outstanding 122.3M 99.05M 106.1M
Diluted Shares Outstanding 129.3M 106.1M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $180.9M $200.4M $200.4M
YoY Change -12.83% 126.39% 126.39%
Cash & Equivalents $180.9M $200.4M $200.4M
Short-Term Investments
Other Short-Term Assets $4.706M $4.024M $13.94M
YoY Change 68.19% 90.89% 38.8%
Inventory
Prepaid Expenses $11.14M $9.912M
Receivables $0.00 $21.09M $21.09M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $196.8M $235.4M $235.4M
YoY Change -10.39% 138.87% 138.87%
LONG-TERM ASSETS
Property, Plant & Equipment $12.42M $13.08M $35.72M
YoY Change -22.41% -24.3% -19.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.583M $3.855M $3.855M
YoY Change -21.47% 3.57% 3.57%
Total Long-Term Assets $38.50M $39.58M $39.58M
YoY Change -19.25% -17.29% -17.29%
TOTAL ASSETS
Total Short-Term Assets $196.8M $235.4M $235.4M
Total Long-Term Assets $38.50M $39.58M $39.58M
Total Assets $235.3M $274.9M $274.9M
YoY Change -11.97% 87.82% 87.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.73M $12.84M $12.84M
YoY Change -1.48% -24.1% -24.1%
Accrued Expenses $1.754M $1.768M $23.54M
YoY Change -17.69% -49.72% 2.14%
Deferred Revenue $140.6M $150.1M
YoY Change 31.44% 375.5%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $165.9M $186.4M $186.4M
YoY Change 25.12% 160.68% 160.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $36.13M $41.01M $41.01M
YoY Change 18917.89% 21481.58% -63.42%
Total Long-Term Liabilities $36.13M $41.01M $41.01M
YoY Change -77.63% -63.42% -63.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $165.9M $186.4M $186.4M
Total Long-Term Liabilities $36.13M $41.01M $41.01M
Total Liabilities $202.0M $227.4M $227.4M
YoY Change -31.32% 23.88% 23.88%
SHAREHOLDERS EQUITY
Retained Earnings -$1.056B -$1.025B
YoY Change 6.2% 5.95%
Common Stock $949.9M $935.4M
YoY Change 13.37% 16.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.39M $39.63M $47.50M
YoY Change
Total Liabilities & Shareholders Equity $235.3M $274.9M $274.9M
YoY Change -11.97% 87.82% 87.82%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$31.56M -$16.26M -$57.51M
YoY Change 15.15% -62.81% -64.46%
Depreciation, Depletion And Amortization $1.042M $1.081M $5.000M
YoY Change -27.29% -28.51% -24.24%
Cash From Operating Activities -$33.43M -$33.24M -$19.43M
YoY Change -139.09% -0.6% -84.79%
INVESTING ACTIVITIES
Capital Expenditures $417.0K $356.0K $1.115M
YoY Change -14.72% 74.51% -18.07%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$417.0K -$356.0K -$1.115M
YoY Change -14.72% -101.43% -11.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $93.57M
YoY Change 82.69%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.51M 93.96M 132.5M
YoY Change -58.61% 170740.0% 97.26%
NET CHANGE
Cash From Operating Activities -33.43M -33.24M -19.43M
Cash From Investing Activities -417.0K -356.0K -1.115M
Cash From Financing Activities 14.51M 93.96M 132.5M
Net Change In Cash -19.41M 60.37M 111.9M
YoY Change -116.17% -806.46% -280.3%
FREE CASH FLOW
Cash From Operating Activities -$33.43M -$33.24M -$19.43M
Capital Expenditures $417.0K $356.0K $1.115M
Free Cash Flow -$33.85M -$33.60M -$20.55M
YoY Change -139.81% -0.15% -84.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001631574
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Revenue Practical Expedient Incremental Cost Of Obtaining Contract
RevenuePracticalExpedientIncrementalCostOfObtainingContract
true
CY2022Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://www.wavelifesciences.com/20231231#GSKEquityInvestmentMember
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37627
CY2023 dei Entity Registrant Name
EntityRegistrantName
WAVE LIFE SCIENCES LTD.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
U0
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1356880
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
7 Straits View #12-00
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Marina One
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
East Tower
CY2023 dei Entity Address Country
EntityAddressCountry
SG
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
018936
CY2023 dei City Area Code
CityAreaCode
+65
CY2023 dei Local Phone Number
LocalPhoneNumber
6236 3388
CY2023 dei Security12b Title
Security12bTitle
$0 Par Value Ordinary Shares
CY2023 dei Trading Symbol
TradingSymbol
WVE
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
258753061
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
122284139
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2023 dei Auditor Name
AuditorName
KPMG LLP
CY2023 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200351000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88497000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21086000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9912000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7932000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4024000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2108000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
235373000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
98537000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
42709000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37846000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13084000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17284000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22637000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26843000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3699000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3660000
CY2023Q4 us-gaap Other Assets
OtherAssets
156000
CY2022Q4 us-gaap Other Assets
OtherAssets
62000
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
39576000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
47849000
CY2023Q4 us-gaap Assets
Assets
274949000
CY2022Q4 us-gaap Assets
Assets
146386000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12839000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16915000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16828000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17552000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
150059000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
31558000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6714000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5496000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
186440000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71521000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
15601000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
79774000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25404000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32118000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
190000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
41005000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
112082000
CY2023Q4 us-gaap Liabilities
Liabilities
227445000
CY2022Q4 us-gaap Liabilities
Liabilities
183603000
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3901348
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3901348
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3901348
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3901348
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
7874000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
7874000
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119162234
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119162234
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86924643
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86924643
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
935367000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
802833000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
129237000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
119442000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-124000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1024850000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-967337000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
39630000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-45091000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
274949000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146386000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
113305000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3649000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
130009000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
115856000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
51292000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50513000
CY2023 us-gaap Operating Expenses
OperatingExpenses
181301000
CY2022 us-gaap Operating Expenses
OperatingExpenses
166369000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-67996000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-162720000
CY2023 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
7928000
CY2022 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1571000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1878000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9806000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1578000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-58190000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-161142000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-677000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
681000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-57513000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-161823000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.05
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106097268
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106097268
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78855810
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78855810
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-57513000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-161823000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-95000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-210000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57608000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-162033000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
32498000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
51220000
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
14268000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
17194000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
223000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
372000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-210000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-161823000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-45091000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
93574000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
9795000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
509000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
748000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-95000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-57513000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
39630000
CY2023 us-gaap Profit Loss
ProfitLoss
-57513000
CY2022 us-gaap Profit Loss
ProfitLoss
-161823000
CY2023 wve Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
4206000
CY2022 wve Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
3540000
CY2023 us-gaap Depreciation
Depreciation
5000000
CY2022 us-gaap Depreciation
Depreciation
6574000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9795000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17194000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21086000
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1980000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1348000
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2010000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3394000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3761000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9348000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-724000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2691000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
54328000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3245000
CY2023 wve Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-5496000
CY2022 wve Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4308000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-190000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
190000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19431000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-127781000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1115000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1361000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
106000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
75044000
CY2022 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
75044000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1115000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1255000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93574000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51220000
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
14268000
CY2023 wve Proceeds From Issuance Of Ordinary Shares Pursuant To The Gsk Collaboration Agreement
ProceedsFromIssuanceOfOrdinarySharesPursuantToTheGskCollaborationAgreement
34623000
CY2023 wve Proceeds From Issuance Of Ordinary Shares Pursuant To At The Market Equity Program Net
ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet
3080000
CY2022 wve Proceeds From Issuance Of Ordinary Shares Pursuant To At The Market Equity Program Net
ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet
1105000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
509000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
223000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
748000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
372000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
132534000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
67188000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-95000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-210000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
111893000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-62058000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
92157000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
154215000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
204050000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
92157000
CY2023 wve Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
210000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
12006000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200400000
CY2023 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
34682000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company’s financial statements and related disclosures requires the Company to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The Company believes that its revenue recognition policy, particularly (a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in the Company’s analysis of contracts with contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”) to estimate the contract expense, involve a greater degree of judgment, and therefore the Company considers them to be its critical accounting policies. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions and conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.17
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1182873
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
204100000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
92200000
CY2022 wve Term Deposits Purchased And Reached Maturity Current
TermDepositsPurchasedAndReachedMaturityCurrent
75000000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents, restricted cash and short-term investments are financial instruments that potentially subject the Company to concentration of credit risk. The Company uses several financial institutions to maintain its cash, cash equivalents, restricted cash and short-term investments, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p>
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3700000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3700000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.51
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14107710
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.58
CY2023Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M23D
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
55793000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
55130000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
42709000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37846000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13084000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17284000
CY2023 us-gaap Depreciation
Depreciation
5000000
CY2022 us-gaap Depreciation
Depreciation
6600000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14065000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12287000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1768000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3516000
CY2023Q4 wve Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
995000
CY2022Q4 wve Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1749000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16828000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17552000
CY2022Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
10683761
CY2022Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
4.68
CY2023 us-gaap Class Of Warrant Or Right Reason For Issuing To Nonemployees
ClassOfWarrantOrRightReasonForIssuingToNonemployees
On June 16, 2022, the Company closed an underwritten offering (the “June 2022 Offering”) in which the Company issued and sold 25,464,483 of the Company’s ordinary shares at a price of $2.15 per share and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 7,093,656 of the Company’s ordinary shares at an offering price of $2.1499 per Pre-Funded Warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each Pre-Funded Warrant. These Pre-Funded Warrants were recorded as a component of shareholders’ equity within additional paid-in capital. The gross proceeds to the Company from the June 2022 Offering were $70.0 million before deducting underwriting discounts and commissions and other offering expenses. The net proceeds to the Company from the June 2022 Offering were approximately $65.5 million after deducting underwriting commissions and offering expenses. The Pre-Funded Warrants are exercisable at any time after their original issuance and on or prior to the five-year anniversary of the original issuance date. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of the Company’s ordinary shares outstanding or more than 19.99% of the combined voting power of the Company’s securities outstanding immediately after giving effect to such exercise, unless and until shareholder approval is obtained.•On December 7, 2023, the Company entered into an underwriting agreement relating to the issuance and sale in an underwritten offering of the Company’s ordinary shares. On December 11, 2023, the Company closed an underwritten public offering (the “December 2023 Offering”) in which the Company issued and sold 20,000,000 of the Company's ordinary shares at a price of $5.00 per share. The gross proceeds to the Company from the December 2023 Offering were $100.0 million before deducting underwriting discounts and commissions and other offering expenses. The net proceeds to the Company from the December 2023 Offering during the year ended December 31, 2023 were approximately $93.6 million after deducting underwriting discounts and offering expenses. On January 4, 2024, the Company closed on the sale of an additional 3,000,000 ordinary shares at a price of $5.00 per share after the underwriters exercised their option to purchase the additional shares in full, which increased the aggregate number of ordinary shares sold in the December 2023 Offering to 23,000,000. The Company’s aggregate gross proceeds from the December 2023 Offering were $115.0 million, before deducting underwriting discounts and commissions and offering expenses; $15.0 million of which relates to the exercise of the underwriters’ option in January 2024. Subsequent to December 31, 2023, the Company received $14.0 million in net proceeds after deducting the underwriting discounts and commissions and offering expenses related to the December 2023 Offering.
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each ordinary share
CY2023Q4 wve Common Stock Votes Per Share
CommonStockVotesPerShare
1
CY2023Q4 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
10
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9682054
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.73
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5769100
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.74
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
160571
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6560153
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.17
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M4D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14418000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9795000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17194000
CY2023 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The lease for the additional space commenced on October 1, 2021, with a term of five years and is considered a separate lease from the Cambridge Lease.
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4500000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4500000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
7365000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
6458000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
2798000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
2508000
CY2023 us-gaap Lease Cost
LeaseCost
10163000
CY2022 us-gaap Lease Cost
LeaseCost
8966000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
8655000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
7226000
CY2022 wve Increase In Operating Right Of Use Assets
IncreaseInOperatingRightOfUseAssets
12006000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
12006000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9311000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9591000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
9584000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8987000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
886000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
38359000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6241000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
32118000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-57513000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-161823000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106097268
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106097268
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78855810
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78855810
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.05
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-58190000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-161142000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-677000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
681000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-677000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
681000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
172547000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
158413000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
8155000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
368000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7512000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7265000
CY2023Q4 wve Deferred Tax Assets Tax Deferred Expense Accumulated Amortization
DeferredTaxAssetsTaxDeferredExpenseAccumulatedAmortization
694000
CY2022Q4 wve Deferred Tax Assets Tax Deferred Expense Accumulated Amortization
DeferredTaxAssetsTaxDeferredExpenseAccumulatedAmortization
782000
CY2023Q4 wve Deferred Tax Assets Tax Deferred Expense Operating Lease Liabilities
DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities
8775000
CY2022Q4 wve Deferred Tax Assets Tax Deferred Expense Operating Lease Liabilities
DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities
10276000
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
10716000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
16786000
CY2023Q4 wve Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
41239000
CY2022Q4 wve Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
36643000
CY2023Q4 wve Deferred Tax Assets Accumulated Depreciation
DeferredTaxAssetsAccumulatedDepreciation
3508000
CY2022Q4 wve Deferred Tax Assets Accumulated Depreciation
DeferredTaxAssetsAccumulatedDepreciation
2807000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
237000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
357000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
253383000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
233697000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
247193000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
226273000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
6190000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
7424000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
6185000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
7333000
CY2022Q4 wve Deferred Tax Liabilities Accumulated Depreciation
DeferredTaxLiabilitiesAccumulatedDepreciation
86000
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
5000
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
5000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6190000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7424000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
226273000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
238170000
CY2023 wve Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
20969000
CY2022 wve Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
3134000
CY2022 wve Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
-14934000
CY2023 wve Deferred Tax Assets Valuation Foreign Currency Translation
DeferredTaxAssetsValuationForeignCurrencyTranslation
49000
CY2022 wve Deferred Tax Assets Valuation Foreign Currency Translation
DeferredTaxAssetsValuationForeignCurrencyTranslation
97000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
247193000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
226273000
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
54700000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
20900000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13945000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
19864000
CY2023 wve Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
114000
CY2022 wve Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
-7320000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1731000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1401000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15790000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13945000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15800000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13900000
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0

Files In Submission

Name View Source Status
0000950170-24-026876-index-headers.html Edgar Link pending
0000950170-24-026876-index.html Edgar Link pending
0000950170-24-026876.txt Edgar Link pending
0000950170-24-026876-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img56446533_0.jpg Edgar Link pending
img56446533_1.jpg Edgar Link pending
img56446533_10.jpg Edgar Link pending
img56446533_11.jpg Edgar Link pending
img56446533_12.jpg Edgar Link pending
img56446533_13.jpg Edgar Link pending
img56446533_14.jpg Edgar Link pending
img56446533_15.jpg Edgar Link pending
img56446533_16.jpg Edgar Link pending
img56446533_17.jpg Edgar Link pending
img56446533_18.jpg Edgar Link pending
img56446533_19.jpg Edgar Link pending
img56446533_2.jpg Edgar Link pending
img56446533_20.jpg Edgar Link pending
img56446533_21.jpg Edgar Link pending
img56446533_22.jpg Edgar Link pending
img56446533_23.jpg Edgar Link pending
img56446533_24.jpg Edgar Link pending
img56446533_25.jpg Edgar Link pending
img56446533_26.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
img56446533_27.jpg Edgar Link pending
img56446533_28.jpg Edgar Link pending
img56446533_29.jpg Edgar Link pending
img56446533_3.jpg Edgar Link pending
img56446533_30.jpg Edgar Link pending
img56446533_31.jpg Edgar Link pending
img56446533_32.jpg Edgar Link pending
img56446533_33.jpg Edgar Link pending
img56446533_34.jpg Edgar Link pending
img56446533_35.jpg Edgar Link pending
img56446533_36.jpg Edgar Link pending
img56446533_37.jpg Edgar Link pending
img56446533_38.jpg Edgar Link pending
img56446533_39.jpg Edgar Link pending
img56446533_4.jpg Edgar Link pending
img56446533_40.jpg Edgar Link pending
img56446533_5.jpg Edgar Link pending
img56446533_6.jpg Edgar Link pending
img56446533_7.jpg Edgar Link pending
img56446533_8.jpg Edgar Link pending
img56446533_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wve-20231231.htm Edgar Link pending
wve-20231231.xsd Edgar Link pending
wve-ex23_1.htm Edgar Link pending
wve-ex31_1.htm Edgar Link pending
wve-ex31_2.htm Edgar Link pending
wve-ex32.htm Edgar Link pending
wve-ex4_2.htm Edgar Link pending
wve-ex97_1.htm Edgar Link pending
wve-20231231_htm.xml Edgar Link completed